Development of strategies for the use of anti-growth factor treatments

Endocrine-Related Cancer

Volumn 12, Issue SUPPL. 1, 2005, Pages

  Jones, H E ^a   Gee, J M W ^a   Taylor, K M ^a   Barrow, D ^a   Williams, H D ^a   Rubini, M ^b   Nicholson, R I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANASTROZOLE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; FULVESTRANT; GEFITINIB; INSULIN; INSULIN RECEPTOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TAMOXIFEN CITRATE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; PHENOTYPE; PROSTATE CANCER; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 25844460747     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01004     Document Type: Conference Paper

References (60)

1. Arteaga CL 2002 Epidermal growth factor receptor dependence in human tumours: more than just expression. Oncologist 7 (Suppl 4) 31-39.
2. Bailey LR, Kris M, Wolf M, Kay A, Averbuch S & Askaa J 2003 Tumour EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small cell lung cancer: IDEAL 1 and 2. Presented at American Association for Cancer Research, Washington DC, USA, 11-14 July 2003. Poster LB-170.
3. Balana ME, Labriola L, Salatino M, Movischoff F, Peters G, Charreau E & Elizalde PV 2001 Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumour cells. Oncogene 20 34-47.
4. Barton J, Blackledge G &, Wakeling A 2001 Growth factors and their receptors: new targets for prostate cancer therapy. Urology 58 (Suppl 2A) 114-122.
5. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T et al. 2002 Phase I safety pharmacokinetic and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor in patients with five selected tumour types. Journal of Clinical Oncology 20 4292-4302.
6. Baselga J, Albanell J, Ruiz A, Gascon P & Guillen V 2003 Phase II and tumour pharmacodynamic study of gefitinib ('Iressa; ZD1839) in patients with advanced breast cancer. Proceedings of the American Society of Clinical Oncology 22 Abs 24.
7. Britton D, Hutcheson IR, Barrow D, Gee JMW & Nicholson RI 2002 Increased oestrogen receptor phosphorylation at serine 118 in tamoxifen resistant MCF-7 breast cancer cells. Biochemical Society Transactions 31 P114.
8. Chakravati A, Loeffler JS & Dyson NJ 2002 Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastome cells through continued activation of phosphoinositide 3-kinase signalling. Cancer Research 62 200-207.
9. Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten C & Bundred NJ 2002 Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and pre-malignant breast. Cancer Research 62 122-128.
10. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR & Tortora G 2000 Antitumour effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clinical Cancer Research 6 2053-2063.
11. Ciardiello F & Tortora G 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clinical Cancer Research 7 2958-2970.
12. Denley A, Wallace JC, Cosgrove LJ & Forbes BE 2003 The insulin receptor isoform exon11-(IR-A) in cancer and other diseases: a review. Hormone and Metabolic Research 35 778-785.
13. Djakiew D 2000 Dysregulated expression of growth factors and their receptors in the development of prostate cancer. The Prostate 42 150-160.
14. Douglass EC 2003 Development of ZD1839 in colorectal cancer. Seminars in Oncology 30 (3 Suppl 6) 17-22.
15. Fan Z, Lu Y, Wu X & Mendelsohn J 1994 Antibody-induced epidermal growth factor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry 269 27595-27602.
16. Fontanini G, De Laurentis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR et al. 1998 Evaluation of epidermal growth-factor related growth factors and receptors and of neoangiogenesis in completely resected stage I-III non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clinical Cancer Research 4 241-249.
17. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D et al. 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 21 2237-2246.
18. Gee JMW, Madden T-A, Robertson JF & Nicholson RI 2002 Clinical response and resistance to SERMs. In Endocrine Therapy of Breast Cancer, pp 155-189. Eds JFR Robertson, RI Nicholson & DF Hayes. London: Martin Dunitz.
19. Gee JMW, Harper ME, Hutcheson IR, Madden T, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE & Nicholson RI 2003 The anti-EGFR agent gefitinib (ZD1839/Iressa™) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 5105-5117.
20. Gee JMW, Gutteridge E, Robertson JF, Wakeling AE, Jones HE & Nicholson RI 2004 Biological markers during early treatment of tamoxifen-resistant breast cancer with gefitinib ('Iressa'). Breast Cancer Research and Treatment 88 (Suppl 1) S32 Abs 307.
21. Griffiths K, Morton MS, Nicholson RI 1997 Androgens, androgen receptors, antiandrogens, and the treatment of prostate cancer. European Urology 32 (Suppl 3) 24-40.
22. Gullick WJ 2001 The Type 1 growth factor receptors and their ligands considered as a complex system. Endocrine-related Cancer 8 75-82.
23. Gutteridge E, Gee KMW, Nicholson RI & Robertson JFR 2004 Biological markers associated with response to gefitinib ('IRESSA') in patients with breast cancer. Proceedings of the American Society of Clinical Oncology 38 Abs 648.
24. Huang S, Armstrong EA, Benavente S, Chinnaiyan P & Harari PM 2004 Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Research 64 5355-5362.
25. Johnston SR, Head J, Pancholi S, Detre S, Martin L, Smith IE & Dowsett M 2003 Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clinical Cancer Research 9 524s-532s.
26. Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE & Nicholson RI 2004a Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrine-related Cancer 11 1-22.
27. Jones HE, Gee JMW, Barrow D, Wakeling AE, Guy S & Nicholson RI 2004b De novo resistance to epidermal growth factor receptor blockade by gefitinib in colorectal cancer cells involves increased insulin receptor isoform A signalling. European Journal of Cancer 2 102 Abs 336.
28. Kelly K & Averbuch S 2004 Gefitinib: Phase II and III results in advanced non-small cell lung cancer. Seminars in Oncology 31 (Suppl 1) 93-99.
29. Knowlden J, Hutcheson IR, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of EGFR/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in Tamoxifen resistant MCF-7 cells. Endocrinology 144 1032-1044.
30. Kris MG, Natale RB, Herbst RS, Lynch Tj, Prager D, Belani CP, Sciller JH, Kelly K, Spiridonidis H, Sandler A et al. 2003 Eficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small lung cell cancer. A randomized trial. Journal of the American Medical Association 290 2149-2158.
31. Lichtner RB 2003 Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother 57 447-451.
32. Liu B, Fang M, Lu Y, Mendelsohn J & Fan ZJ 2001 Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 20 1913-1922.
33. Lu Y, Zi X, Zhao Y, Mascarenhas D & Pollak M 2001 Insulin-like growth factor-1 receptor signaling and resistance to Trastuzumab (Herceptin). Journal of the National Cancer Institute 93 1852-1857.
34. Lu Y, Zi X, Zhao Y & Pollak M 2004 Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signalling pathway in breast cancer cells. Biochemical and Biophysical Research Communications 313 709-715.
35. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. New England Journal of Medicine 350 2129-2139.
36. Massarweh S, Shou J, Mohsin SK, Ge M, Wakeling AE, Osbourne CK & Schiff R 2002 Inhibition of epidermal growth factor/HER2 receptor signalling using ZD1839 ('Iressa') restores tamoxifen sensitivity and delays resistance to oestrogen deprivation in HER2 overexpressing breast tumours. Proceedings of the American Society of Clinical Oncology 21 33.
37. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzman M, Rodriguez S, Arribas J, Palacios J & Baselga J 2004 Combined epidermal growth factor receptor targeting with tyrosine kinase inhibitor gefitinib (ZD 1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single agent receptor targeting. Clinical Cancer Research 10 6487-6501.
38. McClelland RA, Barrow D, Madden T, Dutkowski CM, Pamment J, Knowlden JM, Gee JMW & Nicholson 2001 Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells following long-term culture in the presence of the pure antioestrogen FASLODEX™. Endocrinology 142 2776-2788.
39. Moasser MM, Basso A, Averbuch SD & Rosen N 2001 The tyrosine kinase inhibitor ZD1839('Iressa') inhibits HER-2-driven signalling and suppresses the growth of HER-2-over-expressing cells. Cancer Research 61 7184-7188.
40. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA & Mueller BM 1993 Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunology, Immunotherapy 37 343-349.
41. Nicholson RI, McClelland RA, Gee JMW, Manning DL, Cannon P, Robertson JFR, Ellis IO & Blamey RW 1994 Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy. Breast Cancer Research and Treatment 29 117-125.
42. Nicholson RI, Gee JMW & Harper ME 2001a EGFR and cancer prognosis. European Journal of Cancer 37 (Suppl 4) S9-S15.
43. Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE & Gee JMW 2001b Modulation of epidermal growth factor receptor in endocrine resistant, oestrogen receptor-positive breast cancer. Endocrine-related Cancer 8 175-182.
44. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D & Gee JM 2004 Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 (1 Pt 2) 346S-352S.
45. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 1497-1500.
46. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P & Bonomi P 2004 Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Journal of Clinical Oncology 22 3238-3247.
47. Ranson M 2002 ZD1839 (Iressa™): For more than just non-small cell lung carcinoma. The Oncologist 7 (Suppl 4) 16-24.
48. Ranson M, Hammond L, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H & Rowinsky EK 2002 ZD1839 a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid malignant tumours: Results of phase I trial. Journal of Clinical Oncology 20 2240-2250.
49. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L & Hortobagyi GN 2004 Targeted therapies for cancer 2004 American Journal of Clinical Pathology 122 598-609.
50. Roudabush F L, Pierce K L, Maudsley S, Khan KD & Luttrell LM 2000 Transactivation of the EGF receptor mediates IGF-1-stimulated she phosphorylation and ERK1/2 activation in COS-7 cells. Journal of Biological Chemistry 275 22583-22589.
51. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J & Dmitrovsky E 1997 Over-expression of the epidermal growth factor receptor and its ligand transforming growth factor a is frequent in resectable non-small cell lung cancer but does not predict tumour progression. Clinical Cancer Research 3 515-522.
52. Salomon DS, Bradt R, Ciardiello F & Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology and Haematology 19 183-232.
53. Schiller JH 2003 New directions for ZD1839 in the treatment of solid tumours. Seminars in Oncology 30 (Suppl 1) 49-55.
54. Slamon DJ, Calrk GM, Wong SG, Levin WJ, Ullrich A & McGuire WL 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 177-182.
55. Surmacz E 2003 Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor 1 receptor. Oncogene 22 6589-6597.
56. Taylor KM, Morgan HE, Johnson A, Hadley LJ & Nicholson RI 2003 Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochemical Journal 375 51-59.
57. van Agthoven TT, van Agthoven TL, Portengen H, Foekens JA & Dorssers LC 1992 Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-71.human breast cancer cells. Cancer Research 52 5082-5088.
58. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ & Gibson KH 2002 ZD1839 (Iressa): A orally active inhibitor of epidermal growth factor signalling with potential for cancer therapy. Cancer Research 62 5749-5754.
59. Wang D, Patil S, Li W, Humphrey LE, Brattain MG & Howell GM 2002 Activation of the TGFalpha autocrine loop is downstream of IGF-I receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells. Oncogene 21 2785-2796.
60. Yu H & Rohan T 2000 The role of insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute 92 1472-1489.